
Drosos E Karageorgopoulos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7162004/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Â-D-Clucan Assay for the Diagnosis of Invasive Fungal Infections: A Meta-analysis. Clinical Infectious Diseases, 2011, 52, 750-770.	2.9	997
2	Pandrug Resistance (PDR), Extensive Drug Resistance (XDR), and Multidrug Resistance (MDR) among Gramâ€Negative Bacilli: Need for International Harmonization in Terminology. Clinical Infectious Diseases, 2008, 46, 1121-1122.	2.9	769
3	Deaths Attributable to Carbapenem-Resistant <i>Enterobacteriaceae</i> Infections. Emerging Infectious Diseases, 2014, 20, 1170-1175.	2.0	432
4	Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infectious Diseases, The, 2010, 10, 43-50.	4.6	425
5	Comparison of SCImago journal rank indicator with journal impact factor. FASEB Journal, 2008, 22, 2623-2628.	0.2	396
6	Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infectious Diseases, The, 2008, 8, 751-762.	4.6	378
7	Etiology of Anemia in Patients With Advanced Heart Failure. Journal of the American College of Cardiology, 2006, 48, 2485-2489.	1.2	338
8	Extended-spectrum β-lactamase-producing organisms. Journal of Hospital Infection, 2009, 73, 345-354.	1.4	316
9	Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet, The, 2016, 388, 498-503.	6.3	291
10	Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. International Journal of Antimicrobial Agents, 2010, 35, 194-199.	1.1	261
11	Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. Journal of Antimicrobial Chemotherapy, 2012, 67, 255-268.	1.3	189
12	Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. Journal of Antimicrobial Chemotherapy, 2008, 62, 45-55.	1.3	170
13	Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis. Intensive Care Medicine, 2011, 37, 747-762.	3.9	167
14	Accuracy of β -D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clinical Microbiology and Infection, 2013, 19, 39-49.	2.8	165
15	Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. International Journal of Antimicrobial Agents, 2009, 34, 111-120.	1.1	159
16	Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. International Journal of Antimicrobial Agents, 2009, 34, 506-515.	1.1	159
17	Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. Journal of Antimicrobial Chemotherapy, 2008, 62, 895-904.	1.3	153
18	Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: A matched case-control study. Critical Care Medicine, 2008, 36, 807-811.	0.4	148

#	Article	IF	CITATIONS
19	MRSA in Africa: Filling the Global Map of Antimicrobial Resistance. PLoS ONE, 2013, 8, e68024.	1.1	144
20	Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. International Journal of Antimicrobial Agents, 2010, 35, 240-243.	1.1	143
21	Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 695-701.	1.3	143
22	Therapeutic options for infections with <i>Enterobacteriaceae</i> producing carbapenem-hydrolyzing enzymes. Future Microbiology, 2011, 6, 653-666.	1.0	141
23	Short- versus Long-Course Antibacterial Therapy for Community-Acquired Pneumonia. Drugs, 2008, 68, 1841-1854.	4.9	132
24	Citrobacter infections in a general hospital: characteristics and outcomes. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 61-68.	1.3	132
25	Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet, The, 2010, 375, 248-251.	6.3	127
26	Airborne hydrogen peroxide for disinfection of the hospital environment and infection control: a systematic review. Journal of Hospital Infection, 2011, 78, 171-177.	1.4	126
27	The Impact of Article Length on the Number of Future Citations: A Bibliometric Analysis of General Medicine Journals. PLoS ONE, 2013, 8, e49476.	1.1	121
28	Effect of body mass index on the outcome of infections: a systematic review. Obesity Reviews, 2009, 10, 280-289.	3.1	109
29	Stenotrophomonas maltophilia Infections in a General Hospital: Patient Characteristics, Antimicrobial Susceptibility, and Treatment Outcome. PLoS ONE, 2012, 7, e37375.	1.1	108
30	Economic crises and mortality: a review of the literature. International Journal of Clinical Practice, 2009, 63, 1128-1135.	0.8	96
31	Comparison of antibiotics with placebo for treatment of acute sinusitis: a meta-analysis of randomised controlled trials. Lancet Infectious Diseases, The, 2008, 8, 543-552.	4.6	94
32	Outbreak of OXA-48 carbapenemase-producing Klebsiella pneumoniae in Greece involving an ST11 clone. Journal of Antimicrobial Chemotherapy, 2013, 68, 84-88.	1.3	92
33	Probiotics for the prevention of respiratory tract infections: a systematic review. International Journal of Antimicrobial Agents, 2009, 34, 197.e1-197.e10.	1.1	91
34	Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opinion on Investigational Drugs, 2009, 18, 921-944.	1.9	90
35	Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Review of Anti-Infective Therapy, 2013, 11, 321-331.	2.0	82
36	Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 439-443.	1.3	80

#	Article	IF	CITATIONS
37	Association between thyroid function tests at baseline and the outcome of patients with sepsis or septic shock: a systematic review. European Journal of Endocrinology, 2011, 164, 147-155.	1.9	78
38	Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. Journal of Antimicrobial Chemotherapy, 2012, 67, 2777-2779.	1.3	63
39	Incidence, Clinical, Microbiological Features and Outcome of Bloodstream Infections in Patients Undergoing Hemodialysis. International Journal of Medical Sciences, 2013, 10, 1632-1638.	1.1	63
40	Effectiveness and safety of short <i>vs</i> . long duration of antibiotic therapy for acute bacterial sinusitis: a metaâ€analysis of randomized trials. British Journal of Clinical Pharmacology, 2009, 67, 161-171.	1.1	56
41	Serum Procalcitonin for Prediction of Renal Parenchymal Involvement in Children with Urinary Tract Infections: A Meta-analysis of Prospective Clinical Studies. Journal of Pediatrics, 2009, 155, 875-881.e1.	0.9	55
42	Age Distribution of Cases of 2009 (H1N1) Pandemic Influenza in Comparison with Seasonal Influenza. PLoS ONE, 2011, 6, e21690.	1.1	55
43	Short versus long duration of antibiotic therapy for bacterial meningitis: a meta-analysis of randomised controlled trials in children. Archives of Disease in Childhood, 2009, 94, 607-614.	1.0	53
44	Pandemic A(H1N1) 2009 influenza: review of the Southern Hemisphere experience. Epidemiology and Infection, 2011, 139, 27-40.	1.0	52
45	Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Current Opinion in Infectious Diseases, 2014, 27, 36-45.	1.3	50
46	Clinical Significance of the Pharmacokinetic and Pharmacodynamic Characteristics of Tigecycline. Current Drug Metabolism, 2009, 10, 13-21.	0.7	49
47	Antibiotics versus placebo or watchful waiting for acute otitis media: a meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 2009, 64, 16-24.	1.3	44
48	Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin-susceptible Staphylococcus aureus infections: a meta-analysis and meta-regression. International Journal of Antimicrobial Agents, 2012, 40, 496-509.	1.1	43
49	The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug and Pandrug Resistant Acinetobacter baumannii: A Systematic Review of Clinical Evidence. Microorganisms, 2019, 7, 159.	1.6	42
50	Fluoroquinolones compared with Â-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. Cmaj, 2008, 178, 845-854.	0.9	41
51	Outcome of Antimicrobial Therapy in Documented Biofilm-Associated Infections. Drugs, 2009, 69, 1351-1361.	4.9	37
52	Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. International Journal of Antimicrobial Agents, 2010, 35, 497-499.	1.1	37
53	Seasonality of mortality: the September phenomenon in Mediterranean countries. Cmaj, 2009, 181, 484-486.	0.9	34
54	Iron deficiency and susceptibility to infections: evaluation of the clinical evidence. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1253-1258.	1.3	33

#	Article	IF	CITATIONS
55	ORIGINAL ARTICLE: Comparison of the distribution of citations received by articles published in high, moderate, and low impact factor journals in clinical medicine. Internal Medicine Journal, 2010, 40, 587-591.	0.5	32
56	Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2020, 8, 191.	1.6	29
57	Metaâ€analysis: ertapenem for complicated intraâ€abdominal infections. Alimentary Pharmacology and Therapeutics, 2008, 27, 919-931.	1.9	28
58	In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus. Journal of Antibiotics, 2014, 67, 369-371.	1.0	26
59	Effect of meteorological variables on the incidence of lower urinary tract infections. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 709-712.	1.3	25
60	Extended or continuous versus short-term intravenous infusion of cephalosporins: a meta-analysis. Expert Review of Anti-Infective Therapy, 2013, 11, 585-595.	2.0	25
61	Short epidemiological overview of the current situation on COVID-19 pandemic in Southeast European (SEE) countries. Journal of Infection in Developing Countries, 2020, 14, 433-437.	0.5	22
62	Continuous versus Conventional Infusion of Amphotericin B Deoxycholate: A Meta-Analysis. PLoS ONE, 2013, 8, e77075.	1.1	21
63	Effectiveness and Safety of Short-Course vs Long-Course Antibiotic Therapy for Group A β-Hemolytic Streptococcal Tonsillopharyngitis: A Meta-analysis of Randomized Trials. Mayo Clinic Proceedings, 2008, 83, 880-889.	1.4	19
64	<i>In Vitro</i> Antimicrobial Susceptibility to Isepamicin of 6,296 Enterobacteriaceae Clinical Isolates Collected at a Tertiary Care University Hospital in Greece. Antimicrobial Agents and Chemotherapy, 2012, 56, 3067-3073.	1.4	18
65	Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population�. World Journal of Hepatology, 2015, 7, 1936.	0.8	17
66	Predictors of Impaired Glucose Regulation in Patients with Non-Alcoholic Fatty Liver Disease. Experimental Diabetes Research, 2012, 2012, 1-7.	3.8	14
67	Lefamulin. Comment on: "Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2019, 7, 270― Microorganisms, 2019, 7, 386.	1.6	14
68	Inadequate Statistical Power of Published Comparative Cohort Studies on Ventilatorâ€Associated Pneumonia to Detect Mortality Differences. Clinical Infectious Diseases, 2010, 50, 468-472.	2.9	13
69	Susceptibility of Gram-negative bacteria to isepamicin: a systematic review. Expert Review of Anti-Infective Therapy, 2012, 10, 207-218.	2.0	13
70	Temporal Trends in the Impact Factor of European versus USA Biomedical Journals. PLoS ONE, 2011, 6, e16300.	1.1	12
71	Increasing dominance of English in publications archived by PubMed. Scientometrics, 2009, 81, 219-223.	1.6	11
72	Weight-adjusted versus fixed dose of linezolid for Chinese healthy volunteers of higher and lower body weight: a Phase I pharmacokinetic and pharmacodynamic study. Expert Opinion on Investigational Drugs, 2013, 22, 309-315.	1.9	10

#	Article	IF	CITATIONS
73	Trimethoprim/sulfametrole: evaluation of the available clinical and pharmacokinetic/pharmacodynamic evidence. International Journal of Antimicrobial Agents, 2011, 38, 197-216.	1.1	8
74	Frequency of the off-label use of monoclonal antibodies in clinical practice: a systematic review of the literature. Current Medical Research and Opinion, 2014, 30, 471-480.	0.9	8
75	Decreasing trends of ultrasonographic prevalence of cystic echinococcosis in a rural Greek area. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 307-309.	1.3	6
76	Severe <i>Plasmodium vivax</i> Malaria Complicated with Acute Respiratory Distress Syndrome: A Case Associated with Focal Autochthonous Transmission in Greece. Vector-Borne and Zoonotic Diseases, 2014, 14, 378-381.	0.6	6
77	Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 1389-1398.	1.3	5
78	Antimicrobial activity of prulifloxacin in comparison with other fluoroquinolones against community-acquired urinary and respiratory pathogens isolated in Greece. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1417-1422.	1.3	5
79	Transvenous extraction of permanent pacemaker and defibrillator leads: Reduced procedural complexity and higher procedural success rates in patients with infective versus noninfective indications. Journal of Cardiovascular Electrophysiology, 2021, 32, 491-499.	0.8	5
80	How Well do Clinical Researchers Understand Risk Estimates?. Epidemiology, 2009, 20, 930-931.	1.2	4
81	In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus. Journal of Antibiotics, 2011, 64, 559-562.	1.0	4
82	Surveillance of Community Outbreaks of Respiratory Tract Infections Based on House-Call Visits in the Metropolitan Area of Athens, Greece. PLoS ONE, 2012, 7, e40310.	1.1	4
83	Comparison of adverse events between oral and intravenous formulations of antimicrobial agents: a systematic review of the evidence from randomized trials. Pharmacoepidemiology and Drug Safety, 2009, 18, 873-879.	0.9	3
84	A Prospective Observational Study of Chronic Prostatitis with Emphasis on Epidemiological and Microbiological Features. Urologia, 2013, 80, 225-232.	0.3	3
85	Trends of tuberculin skin test positivity rate among schoolchildren in Attica, Greece. Scandinavian Journal of Infectious Diseases, 2009, 41, 195-200.	1.5	2
86	Neuroimaging Findings in Racemose Neurocysticercosis: Case Description and Literature Review. Journal of Neurosonology and Neuroimaging, 2021, 13, 37-46.	0.0	2
87	Probiotics for the prevention of ventilator-associated pneumonia. Expert Review of Respiratory Medicine, 2010, 4, 567-571.	1.0	1
88	Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. Journal of Antimicrobial Chemotherapy, 2013, 68, 976-976.	1.3	1
89	Tooth and Consequences. American Journal of Medicine, 2008, 121, 577-579.	0.6	0